BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10456617)

  • 1. Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma.
    Pavey SJ; Hawson GA; Marsh NA
    Blood Coagul Fibrinolysis; 1999 Jul; 10(5):261-7. PubMed ID: 10456617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma.
    Pavey SJ; Hawson GA; Marsh NA
    Blood Coagul Fibrinolysis; 2001 Jan; 12(1):51-8. PubMed ID: 11229827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
    Montemurro P; Conese M; Altomare DF; Memeo V; Colucci M; Semeraro N
    Int J Clin Lab Res; 1995; 25(4):195-200. PubMed ID: 8788547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
    Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.
    Carmassi F; Morale M; Puccetti R; De Negri F; Monzani F; Navalesi R; Mariani G
    Thromb Res; 1992 Sep; 67(6):643-54. PubMed ID: 1440530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.
    Tohgi H; Takahashi H; Chiba K; Tamura K
    Stroke; 1993 Jun; 24(6):801-4. PubMed ID: 8506551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
    Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
    Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
    Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the fibrinolytic system in patients with fulminant liver failure.
    Pernambuco JR; Langley PG; Hughes RD; Izumi S; Williams R
    Hepatology; 1993 Dec; 18(6):1350-6. PubMed ID: 8244260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection.
    Tsuji K; Eguchi Y; Kodama M
    J Am Coll Surg; 1996 Sep; 183(3):230-8. PubMed ID: 8784316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
    Kario K; Matsuo T
    Atherosclerosis; 1993 Nov; 103(2):131-8. PubMed ID: 8292090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.